2022

Specifics of use and dosage of the medicinal product DAPTOMYCIN-VISTA

Інформаційний лист-повідомлення для медичних працівників про особливості застосування та дозування лікарського засобу на основі даптоміцину, його показання та важливі ідентифіковані ризики (токсичність щодо скелетних м'язів, дисрегуляція коагуляції), а також рекомендації щодо їх мінімізації. складено автоматично

Important information on minimizing the risks of decreased white blood cell and lymphocyte counts and the development of serious and opportunistic infections with the use of dimethyl fumarate

Information letter-notification for healthcare professionals on the safe use of dimethyl fumarate. It contains recommendations for minimizing the risks of reduced leukocyte and lymphocyte counts, the development of serious infections and progressive multifocal leukoencephalopathy, including blood test monitoring. compiled automatically

Important information on minimizing the risk of aortic aneurysm and dissection and heart valve regurgitation/incompetence with the use of levofloxacin

Information letter for healthcare professionals on minimizing the risks of aortic aneurysm and dissection, as well as heart valve regurgitation/insufficiency, with the use of systemic fluoroquinolones, in particular levofloxacin. Contains PRAC-confirmed data on the causal relationship of these safety issues and recommendations on the use of the products. compiled automatically

Important information on minimizing the risk of severe and life-threatening adverse reactions with the use of the medicinal product FLUOROURACILVISTA in patients with partial or complete dihydropyrimidine dehydrogenase deficiency

Information letter-notification for healthcare professionals on minimizing the risk of severe and life-threatening adverse reactions when using a fluorouracil-containing medicinal product in patients with partial or complete dihydropyrimidine dehydrogenase deficiency, with recommendations for testing the level of this enzyme before starting treatment. compiled automatically

Regarding safety precautions that must be known before and during treatment with zoledronic acid

Information letter-notification for healthcare professionals on safety precautions when using zoledronic acid, in particular regarding the risk of osteonecrosis of the jaw and recommendations for patients before and during treatment. compiled automatically

Vizkyu

VALPROATE (Depakine®, Depakine Chrono® 300 mg, Depakine Chrono ® 500 mg, Depakine® Enteric 300)

Educational guide for healthcare professionals within the Pregnancy Prevention Programme during valproate use. Contains information on teratogenic risks, congenital malformations and nervous system disorders, conditions of prescribing, contraception, management of female patients and pregnant women, and switching to alternative treatment. generated automatically

SINRAIZ

Training materials for physicians on the use of the medicinal product Cinryze at home, updated with recommendations for children aged 2 to 17 years. Contains information on storage, preparation, dosing, administration, disposal, emergency response, and keeping the patient diary. generated automatically

Patient information card, important information on minimizing the risk of infection and congestive heart failure when using Erelzi (etanercept)

The patient leaflet contains safety information on the use of Erelzi (etanercept): the risk of serious infections, the need for tuberculosis screening, and symptoms of congestive heart failure that require an immediate response. Intended for patients receiving this treatment and their physicians. compiled automatically

ZOLEDRONIC ACID – VISTA AS

An information letter-notification for healthcare professionals on safety precautions when using zoledronic acid. Contains recommendations for minimizing the risk of osteonecrosis of the jaw before and during treatment. generated automatically